Fibrocell Science (FCSC) Stock Spikes Following Rare Pediatric Disease Treatment Designation

NEW YORK (TheStreet) -- Fibrocell Science (FCSC) shares are up 19.7% to $4.26 in afternoon trading on Wednesday after the biompharmaceutical company announced that the Food and Drug Administration granted rare pediatric disease designation for its experimental recessive dystrophic epidermolysis bullosa (RDEB) treatment candidate FCX-007.

The FDA defines a rare pediatric disease as an affliction that affects fewer than 200,000 people under the age of 18. Treatments given the rare pediatric disease priority designation receive a priority new drug application review.

RDEB is the most severe form of dystrophic epidermolysis bullosa that causes debilitating pain and can potentially be fatal.

"We are pleased that the FDA has granted our request to designate FCX-007 for the treatment of RDEB as a drug for a rare pediatric disease. FCX-007 may offer RDEB patients and their families the first therapy to treat the underlying cause of the disease, bringing hope and relief to what is today a painful, disabling and often fatal congenital disorder," said CEO David Pernock.

"We are also pleased that the incentives offered by both the Orphan Drug and rare pediatric disease designations-including the potential to obtain a valuable Rare Pediatric Disease Priority Review Voucher from the FDA-could provide additional ways to create value for our shareholders," Pernock continued.

FCSC Chart FCSC data by YCharts

Must Read: Warren Buffett's Top 25 Stocks for 2015

If you liked this article you might like

These 5 Stocks Under $10 Could Make You a Lot of Money

These 5 Stocks Under $10 Could Make You a Lot of Money

These 5 Stocks Under $10 Are Set to Soar Higher

These 5 Stocks Under $10 Are Set to Soar Higher

5 Stocks Under $10 Set to Soar

5 Stocks Under $10 Set to Soar

5 Stocks Ready for Breakouts

5 Stocks Ready for Breakouts

Playing Biotechs with the House's Money

Playing Biotechs with the House's Money